The combination of rigidity and flexibility in the world of veins: exploring a stent that has gained countless fans on VC 2025

The 9th Venous Conference (VC 2025), also known as the "9th Venous Conference and 25th Symposium on New Technologies for Peripheral Vascular Disease Intervention", is a professional conference hosted by the Beijing Health Promotion Association and guided by multiple authoritative academic institutions such as the China Venous Intervention Alliance. The conference will be held grandly at the Jiangsu Provincial Convention Center from September 5th to 7th, 2025.

At the 9th Venous Conference (VC 2025), Ensheng Medical showcased its core product V-Mixtent ® Venous stent system and V-CLOFF ® The deep vein thrombosis clearance system, consisting of two products, has attracted the attention of numerous attending experts as a "dual star" solution for venous therapy.

Ensheng Medical's V-Mixtent ® The venous stent adopts a unique modular hybrid design of "carving+weaving". The carved segment near the heart can provide strong radial support, ensuring stable anchoring and smooth blood flow in compressed areas such as the common iliac vein; The braided segment at the distal end has excellent flexibility and flexural resistance, and can adapt well to the physiological bending and dynamic movement of the external iliac vein and femoral vein. This design cleverly balances the clinical needs of "strong support" and "high flexibility", aiming to address the limitations of traditional single structure scaffolds. The ring connection process of the stent also helps to reduce the risk of fatigue fracture after long-term implantation.

V-Mixtent ® The scope of application of venous stents is comprehensive, covering

•Non thrombotic iliac vein compression syndrome (NIVCS)

• Deep vein thrombosis (DVT)

• Post Deep Venous Thrombosis Syndrome (PTS)

According to the three-year follow-up data, V-Mixtent ® Venous stents have shown high patency in different lesions (including thrombotic and non thrombotic), and no adverse events such as stent rupture or displacement have been reported, confirming the effectiveness and long-term safety of their design.